Lim Yu Jin, Koh Jaemoon, Choi Minji, Kim Sehui, Chie Eui Kyu
Department of Radiation Oncology, Kyung Hee University College of Medicine, Kyung Hee University Medical Center, Seoul, South Korea.
Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea.
Front Oncol. 2022 Oct 25;12:1018700. doi: 10.3389/fonc.2022.1018700. eCollection 2022.
Although rectal cancer remains somewhat sanctuary to the contemporary immunotherapy, there is increasing knowledge on clinical implications of anti-tumor immunity. This study evaluated the prognostic relevance of two immune-inhibitory functions, myeloid-derived suppressor cells (MDSCs) and programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis.
Study cohort is comprised of 165 patients with locally advanced rectal cancer who underwent neoadjuvant chemoradiotherapy followed by definitive resection. Using postsurgical tissue microarrays, the number of MDSCs, PD-1/CD8 tumor-infiltrating lymphocyte (TIL) ratio, and PD-L1 expression scores in stromal immune cells and tumor cells were assessed.
Positive correlation was observed between the PD-1/CD8 TIL ratio and number of MDSCs ( < 0.001). The greater the immune infiltrates, the higher the PD-L1 immune cell score ( < 0.001). MDSC, PD-1/CD8 TIL, PD-L1 immune cell score, and PD-L1 tumor H-score were associated with worse disease-free survival (DFS) ( < 0.001, = 0.042, 0.047, and < 0.001, respectively). To integrate the adverse effects of MDSC, PD-1/CD8 TIL, and either PD-L1 immune cell score (set I) or tumor H-score (set II), prognostic risks were stratified according to the number of factors: 0, 1, and 2-3 ( < 0.001 for I and II). On multivariate analyses, patients with multiple risk factors for set I and II had worse prognosis ( < 0.001; 2-3 vs. 0 for models I and II), and the two prognostic models had acceptable predictability.
In this study, integration of the prognostic impact of MDSCs and PD-1/PD-L1 stratified the long-term risks of patients with locally advanced rectal cancer. Thus, further exploration could be focused to the identified subset of patients carrying worse prognosis, where potential benefits could be derived by targeting the two components contributing to the immunosuppressive microenvironment.
尽管直肠癌在当代免疫疗法中仍在一定程度上处于“免疫赦免”状态,但人们对抗肿瘤免疫的临床意义的认识日益增加。本研究评估了两种免疫抑制功能,即髓源性抑制细胞(MDSCs)和程序性细胞死亡蛋白1(PD-1)/程序性死亡配体1(PD-L1)轴的预后相关性。
研究队列由165例局部晚期直肠癌患者组成,这些患者接受了新辅助放化疗,随后进行了根治性切除术。使用术后组织微阵列,评估MDSCs的数量、PD-1/CD8肿瘤浸润淋巴细胞(TIL)比率以及基质免疫细胞和肿瘤细胞中PD-L1的表达评分。
观察到PD-1/CD8 TIL比率与MDSCs数量之间呈正相关(<0.001)。免疫浸润越多,PD-L1免疫细胞评分越高(<0.001)。MDSC、PD-1/CD8 TIL、PD-L1免疫细胞评分和PD-L1肿瘤H评分与无病生存期(DFS)较差相关(分别为<0.001、=0.042、0.047和<0.001)。为了综合MDSC、PD-1/CD8 TIL以及PD-L1免疫细胞评分(组I)或肿瘤H评分(组II)的不良影响,根据因素数量对预后风险进行分层:0、1和2 - 3(组I和组II均<0.001)。在多变量分析中,组I和组II具有多个风险因素的患者预后较差(<0.001;组I和组II中2 - 3个因素与0个因素相比),并且这两个预后模型具有可接受的预测性。
在本研究中,整合MDSCs和PD-1/PD-L1的预后影响对局部晚期直肠癌患者的长期风险进行了分层。因此,进一步的探索可以集中在预后较差的特定患者亚组,通过针对导致免疫抑制微环境的两个组成部分可能会获得潜在益处。